针对IgA病的药物的有效性和安全性:随机对照试验的网络元分析
Bo Chen1,2, Yan Zhu1, Yang Yang1
1Department of Nephrology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Frontiers in medicine
|July 3, 2025
概括
这项研究发现,类固醇加上RAS抑制剂是IgA脏病 (IgAN) 治疗的核心,改善缓解并减少损伤. 其他治疗方法,如特利塔西塞普和斯帕森坦,对特定的患者有好处.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在全球范围内,IgA病 (IgAN) 是末期病 (ESRD) 的首要原因.
- 病理机制包括粘膜免疫异常和补体激活.
- 目前的治疗方法缺乏治疗方案,需要对疗效进行评估.
研究的目的:
- 系统地比较现有的Igan治疗的疗效.
- 评估对临床缓解 (CR),蛋白尿,损伤 (KD) 和不良事件 (AE) 的影响.
- 为优化IGAN中的分层治疗策略提供证据.
主要方法:
- 在2025年2月20日之前,对主要数据库 (PubMed,科学网,Embase,Cochrane图书馆) 进行系统搜索.
- 包括57项随机对照试验 (RCT),涵盖19项干预措施.
- 用于评估结果的双向和网络元分析 (CR,24小时UPE,ESRD/KD,AE).
主要成果:
- 类固醇加上RAS抑制剂 (STE+RASI) 显著改善了CR,减少了24小时尿道蛋白质分泌 (24-h UPE),并降低了ESRD/KD的风险.
- 泰利塔西塞普和STE+RASI显示24小时UPE显著减少.
- 伊普塔科潘和SGLT2抑制剂显示出最少的不良事件发生率.
结论:
- STE+RASI是Igan的核心治疗策略,改善了关键的临床结果.
- 泰利塔西塞普,斯帕森坦和桃体切除术与类固醇脉冲疗法 (TSP) 是特定患者的潜在增强选择.
- 在本分析中,有针对性的阴道布德索尼德 (Nefecon) 没有显示出显著的脏保护优势.
相关概念视频
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
59
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
59
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
524
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
524
01:25Antihypertensive Drugs: Direct Renin Inhibitors
845
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
845
01:28Chronic Kidney Disease III: Interprofessional Care
82
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
82
01:27Open Angle Glaucoma: Treatment
586
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
586
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
239
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
239